2.50
Hdl Handle:
http://hdl.handle.net/10541/82499
Title:
Temozolomide: a novel oral alkylating agent.
Authors:
Danson, Sarah; Middleton, Mark R
Abstract:
Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combination chemotherapy. Trials to date have focussed on its activity in advanced metastatic melanoma and high-grade malignant glioma. Investigations into other indications, in particular solid tumors with central nervous system metastases, are ongoing. Studies of new drug schedules and of drugs to ameliorate temozolomide resistance offer the prospect of increased efficacy.
Affiliation:
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK.
Citation:
Temozolomide: a novel oral alkylating agent. 2001, 1 (1):13-9 Expert Rev Anticancer Ther
Journal:
Expert Review of Anticancer Therapy
Issue Date:
Jun-2001
URI:
http://hdl.handle.net/10541/82499
DOI:
10.1586/14737140.1.1.13
PubMed ID:
12113120
Type:
Article
Language:
en
ISSN:
1473-7140
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDanson, Sarah-
dc.contributor.authorMiddleton, Mark R-
dc.date.accessioned2009-09-24T11:43:11Z-
dc.date.available2009-09-24T11:43:11Z-
dc.date.issued2001-06-
dc.identifier.citationTemozolomide: a novel oral alkylating agent. 2001, 1 (1):13-9 Expert Rev Anticancer Theren
dc.identifier.issn1473-7140-
dc.identifier.pmid12113120-
dc.identifier.doi10.1586/14737140.1.1.13-
dc.identifier.urihttp://hdl.handle.net/10541/82499-
dc.description.abstractTemozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combination chemotherapy. Trials to date have focussed on its activity in advanced metastatic melanoma and high-grade malignant glioma. Investigations into other indications, in particular solid tumors with central nervous system metastases, are ongoing. Studies of new drug schedules and of drugs to ameliorate temozolomide resistance offer the prospect of increased efficacy.en
dc.language.isoenen
dc.subjectBrain Canceren
dc.subject.meshAdministration, Oral-
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshBrain Neoplasms-
dc.subject.meshDacarbazine-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshGlioma-
dc.subject.meshMelanoma-
dc.titleTemozolomide: a novel oral alkylating agent.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK.en
dc.identifier.journalExpert Review of Anticancer Therapyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.